First Time Loading...

Enliven Therapeutics Inc
NASDAQ:ELVN

Watchlist Manager
Enliven Therapeutics Inc Logo
Enliven Therapeutics Inc
NASDAQ:ELVN
Watchlist
Price: 23.43 USD -1.97% Market Closed
Updated: May 13, 2024

Intrinsic Value

ELVN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Enliven Therapeutics, Inc. operates as a a clinical stage precision oncology company. [ Read More ]

The intrinsic value of one ELVN stock under the Base Case scenario is 5.42 USD. Compared to the current market price of 23.43 USD, Enliven Therapeutics Inc is Overvalued by 77%.

Key Points:
ELVN Intrinsic Value
Base Case
5.42 USD
Overvaluation 77%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Enliven Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ELVN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Enliven Therapeutics Inc

Provide an overview of the primary business activities
of Enliven Therapeutics Inc.

What unique competitive advantages
does Enliven Therapeutics Inc hold over its rivals?

What risks and challenges
does Enliven Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Enliven Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Enliven Therapeutics Inc.

Provide P/S
for Enliven Therapeutics Inc.

Provide P/E
for Enliven Therapeutics Inc.

Provide P/OCF
for Enliven Therapeutics Inc.

Provide P/FCFE
for Enliven Therapeutics Inc.

Provide P/B
for Enliven Therapeutics Inc.

Provide EV/S
for Enliven Therapeutics Inc.

Provide EV/GP
for Enliven Therapeutics Inc.

Provide EV/EBITDA
for Enliven Therapeutics Inc.

Provide EV/EBIT
for Enliven Therapeutics Inc.

Provide EV/OCF
for Enliven Therapeutics Inc.

Provide EV/FCFF
for Enliven Therapeutics Inc.

Provide EV/IC
for Enliven Therapeutics Inc.

Show me price targets
for Enliven Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Enliven Therapeutics Inc?

How accurate were the past Revenue estimates
for Enliven Therapeutics Inc?

What are the Net Income projections
for Enliven Therapeutics Inc?

How accurate were the past Net Income estimates
for Enliven Therapeutics Inc?

What are the EPS projections
for Enliven Therapeutics Inc?

How accurate were the past EPS estimates
for Enliven Therapeutics Inc?

What are the EBIT projections
for Enliven Therapeutics Inc?

How accurate were the past EBIT estimates
for Enliven Therapeutics Inc?

Compare the revenue forecasts
for Enliven Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Enliven Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Enliven Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Enliven Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Enliven Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Enliven Therapeutics Inc with its peers.

Analyze the financial leverage
of Enliven Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Enliven Therapeutics Inc.

Provide ROE
for Enliven Therapeutics Inc.

Provide ROA
for Enliven Therapeutics Inc.

Provide ROIC
for Enliven Therapeutics Inc.

Provide ROCE
for Enliven Therapeutics Inc.

Provide Gross Margin
for Enliven Therapeutics Inc.

Provide Operating Margin
for Enliven Therapeutics Inc.

Provide Net Margin
for Enliven Therapeutics Inc.

Provide FCF Margin
for Enliven Therapeutics Inc.

Show all solvency ratios
for Enliven Therapeutics Inc.

Provide D/E Ratio
for Enliven Therapeutics Inc.

Provide D/A Ratio
for Enliven Therapeutics Inc.

Provide Interest Coverage Ratio
for Enliven Therapeutics Inc.

Provide Altman Z-Score Ratio
for Enliven Therapeutics Inc.

Provide Quick Ratio
for Enliven Therapeutics Inc.

Provide Current Ratio
for Enliven Therapeutics Inc.

Provide Cash Ratio
for Enliven Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Enliven Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Enliven Therapeutics Inc?

What is the current Free Cash Flow
of Enliven Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Enliven Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Enliven Therapeutics Inc

Current Assets 266.2m
Cash & Short-Term Investments 253.1m
Other Current Assets 13m
Non-Current Assets 5.7m
PP&E 1.1m
Other Non-Current Assets 4.7m
Current Liabilities 25.9m
Accounts Payable 532k
Accrued Liabilities 15.4m
Other Current Liabilities 10m
Non-Current Liabilities 67k
Other Non-Current Liabilities 67k
Efficiency

Earnings Waterfall
Enliven Therapeutics Inc

Revenue
0 USD
Operating Expenses
-83.5m USD
Operating Income
-83.5m USD
Other Expenses
11.9m USD
Net Income
-71.6m USD

Free Cash Flow Analysis
Enliven Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ELVN Profitability Score
Profitability Due Diligence

Enliven Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Enliven Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

ELVN Solvency Score
Solvency Due Diligence

Enliven Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Enliven Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ELVN Price Targets Summary
Enliven Therapeutics Inc

Wall Street analysts forecast ELVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELVN is 35.02 USD with a low forecast of 32.32 USD and a high forecast of 38.85 USD.

Lowest
Price Target
32.32 USD
38% Upside
Average
Price Target
35.02 USD
49% Upside
Highest
Price Target
38.85 USD
66% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ELVN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ELVN Price
Enliven Therapeutics Inc

1M 1M
+18%
6M 6M
+115%
1Y 1Y
+18%
3Y 3Y
-24%
5Y 5Y
-61%
10Y 10Y
-61%
Annual Price Range
23.43
52w Low
10.13
52w High
24.7
Price Metrics
Average Annual Return 11.14%
Standard Deviation of Annual Returns 87.56%
Max Drawdown -98%
Shares Statistics
Market Capitalization 1.1B USD
Shares Outstanding 46 704 800
Percentage of Shares Shorted 24.87%

ELVN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Enliven Therapeutics Inc Logo
Enliven Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.1B USD

Dividend Yield

0%

Description

Enliven Therapeutics, Inc. operates as a a clinical stage precision oncology company. The company is headquartered in Boulder, Colorado and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm focuses on addressing existing and emerging unmet needs with a precision oncology approach. The firm is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC).

Contact

COLORADO
Boulder
6200 Lookout Road
+17206478519
https://www.enliventherapeutics.com/

IPO

2020-03-12

Employees

6

Officers

Co-Founder, CEO, Secretary & Director
Mr. Samuel S. Kintz M.B.A.
CFO & Head of Corporate Development
Mr. Benjamin Hohl
Chief Medical Officer
Dr. Helen Louise Collins M.D.
Co-Founder, Chief Scientific Officer & Directors
Dr. Joseph P. Lyssikatos Ph.D.
Co-Founder & COO
Mr. Anish Patel Pharm.D.
Chief Legal Officer & Head of Business Development
Dr. Galya D. Blachman Esq., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one ELVN stock?

The intrinsic value of one ELVN stock under the Base Case scenario is 5.42 USD.

Is ELVN stock undervalued or overvalued?

Compared to the current market price of 23.43 USD, Enliven Therapeutics Inc is Overvalued by 77%.